A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Colorado Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Ferring Pharmaceuticals
Enrollment Form
This study is currently enrolling.